AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Surmodics jumps 12% amid pre-trial hearing in FTC's suit to block GTCR sale
ByAinvest
Friday, Jul 25, 2025 4:37 pm ET1min read
Surmodics shares rose 12% amid a pre-trial hearing in the Federal Trade Commission's lawsuit to block GTCR's purchase of Surmodics. The company proposed a divestiture to appease the FTC.
Surmodics shares (NYSE: SUR) surged by 12% on July 2, 2025, following a pre-trial hearing in the Federal Trade Commission's (FTC) lawsuit to block GTCR BC Holdings, LLC's acquisition of Surmodics, Inc. [1]. The hearing highlighted the FTC's concerns about the deal, which seeks to combine the two largest manufacturers of critical medical device coatings.The FTC alleges that the acquisition would create a combined company controlling more than 50% of the market for outsourced hydrophilic coatings. These coatings are crucial for lifesaving medical devices such as catheters and guidewires. In response to the FTC's concerns, GTCR proposed a divestiture to appease the regulatory body [1].
The FTC initially filed an administrative complaint against GTCR and Surmodics in 2025, alleging that the deal was anticompetitive. The complaint was later amended to include the states of Illinois and Minnesota as co-plaintiffs and GTCR, LLC as an additional defendant [1]. The case remains pending, and the FTC continues to scrutinize the proposed acquisition.
In addition to the FTC's lawsuit, Surmodics has been in the news for its financial performance. The company declared a $0.58/share quarterly dividend, marking an 185% increase from the prior dividend of $0.57. This dividend announcement was made on July 1, 2025, and is payable on September 15 for shareholders of record by September 2, with an ex-dividend date of September 2 [2].
The recent developments in the FTC lawsuit and the dividend announcement have contributed to the positive market sentiment towards Surmodics shares. Investors are closely monitoring the case's progress and the company's financial health.
References:
[1] https://www.ftc.gov/merger
[2] https://seekingalpha.com/news/4472232-kellanova-raises-quarterly-dividend-by-185-to-058share
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet